Nothing Special   »   [go: up one dir, main page]

Long et al., 2021 - Google Patents

The vital role of white adipose tissue in the regulation of intestinal homeostasis and systemic metabolism

Long et al., 2021

View PDF
Document ID
4401680987630961525
Author
Long K
et al.
Publication year

External Links

Snippet

Method: To address this question, I employed our recently developed lipodystrophic mouse model, in which adipocyte MDM2 is genetically deleted (so-called Adipo-MDM2-KO mice). To investigate the role of sWAT in the regulation of intestinal function, sWAT from its wild …
Continue reading at theses.lib.polyu.edu.hk (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Kawano et al. Microbiota imbalance induced by dietary sugar disrupts immune-mediated protection from metabolic syndrome
Lindsay et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease
van den Hoogen et al. Modulation of multiple sclerosis and its animal model experimental autoimmune encephalomyelitis by food and gut microbiota
Castillo‐Courtade et al. Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse model
McLaughlin et al. Role of innate and adaptive immunity in obesity-associated metabolic disease
Lai et al. Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study
Virili et al. Gut microbiome and thyroid autoimmunity
Dolpady et al. Oral probiotic VSL# 3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2, 3‐dioxygenase‐enriched tolerogenic intestinal environment
Lee et al. Mixture of two Lactobacillus plantarum strains modulates the gut microbiota structure and regulatory T cell response in diet‐induced obese mice
Ebrahimzadeh Leylabadlo et al. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies
Li et al. Human umbilical mesenchymal stem cells display therapeutic potential in rheumatoid arthritis by regulating interactions between immunity and gut microbiota via the aryl hydrocarbon receptor
Scalera et al. What does irritable bowel syndrome share with non-alcoholic fatty liver disease?
Su et al. Mesenteric lymph node CD4+ T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease
Hohman et al. A gut‐centric view of aging: Do intestinal epithelial cells contribute to age‐associated microbiota changes, inflammaging, and immunosenescence?
Huang et al. Probiotic and glutamine treatments attenuate alcoholic liver disease in a rat model
Zou et al. Maternal fiber deprivation alters microbiota in offspring, resulting in low-grade inflammation and predisposition to obesity
Silva Intestinal dendritic cells and epithelial barrier dysfunction in Crohn's disease
Tattoli et al. Microbiota, innate immune system, and gastrointestinal muscle: ongoing studies
Kaymak et al. Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases
Zhao et al. Preventive effects of Schistosoma japonicum ova on trinitrobenzenesulfonic acid‐induced colitis and bacterial translocation in mice
US20220265735A1 (en) Canine microbe preparations for increasing oxytocin
Oliveira et al. Lactobacillus paracasei reduces intestinal inflammation in adoptive transfer mouse model of experimental colitis
Wang et al. Apoptotic biliary epithelial cells and gut dysbiosis in the induction of murine primary biliary cholangitis
Ogita et al. Streptococcus thermophilus ST28 ameliorates colitis in mice partially by suppression of inflammatory Th17 cells
Lin et al. Effects of intravenous injection of Porphyromonas gingivalis on rabbit inflammatory immune response and atherosclerosis